Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 3, 2006, Pages 917-924

  Wild, John M ^a   Robson, Catherine R ^a   Jones, Adrian L ^b   Cunliffe, Ian A ^c   Smith, Philip E M ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; VALPROIC ACID; VIGABATRIN; ANTICONVULSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPILEPSY; EYE EXAMINATION; HUMAN; IMAGE QUALITY; MONOTHERAPY; OPTICAL COHERENCE TOMOGRAPHY; PERIMETRY; PRIORITY JOURNAL; RETINA INJURY; RETINA MACULA LUTEA; RETINA NERVE CELL; SCANNING LASER OPHTHALMOSCOPY; VISUAL FIELD DEFECT; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; MALE; NERVE FIBER; OPHTHALMOSCOPY; PATHOLOGY; PROSPECTIVE STUDY; RETINA GANGLION CELL; SENSITIVITY AND SPECIFICITY; VISUAL DISORDER; VISUAL FIELD;

ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CROSS-SECTIONAL STUDIES; EPILEPSY; FEMALE; HUMANS; MALE; NERVE FIBERS; OPHTHALMOSCOPY; PERIMETRY; PROSPECTIVE STUDIES; RETINAL GANGLION CELLS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, OPTICAL COHERENCE; VALPROIC ACID; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 33645398585     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0854     Document Type: Article

References (42)

1. Ben-Menachem E, Persson LI, Schechter PJ, et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol. 1989;27(suppl):79-85.
2. Riekkinen PJ, Ylinen A, Halonen T, Sivenius J, Pitkanen A. Cerebrospinal fluid, GABA and seizure control with vigabatrin. Br J Clin Pharmacol. 1989;27(suppl):87-94.
3. Kälviäinen R, Aikiä M, Saukkonene AM, Mervaala E, Riekkinen PJ. Vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy. Arch Neurol. 1995;52:989-996.
4. Hancock E, Osborne J, Milner P. Treatment of infantile spasms. Cochrane Database Systematic Reviews 2003;CD0011770.
5. Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology: Child Neurology Society. Neurology. 2004;62:1668-1681.
6. Elterman RD, Shields WD, Mansfield KA, Nakagawa J. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2002;57:1416-1421.
7. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol. 1989;27(suppl):19-22.
8. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314:180-181.
9. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmic findings. Neurology. 1998;50:614-618.
10. Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology. 1999;52:1201-1205.
11. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology. 1999;106:1792-1798.
12. Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainen E, Partanen K, Riekkinen P. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology. 1999;53:922-926.
13. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M. Visual dysfunction in patients receiving vigabatrin. Neurology. 1999;53:2082-2087.
14. Lawden MC, Eke T, Degg C, Harding GFA, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999;67:716-722.
15. Wild JM, Martinez C, Reinshagen G, Harding GFA. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia. 1999;40:1784-1794.
16. Stefan H, Bernatik J, Knorr HLJ. Visual field constriction and antiepileptic drug treatment. Neurol Psychiatry Brain Res. 2000;7:185-190.
17. Fledelius HC. Vigabatrin-associated visual field constriction in a longitudinal series: reversibility suggested after drug withdrawal. Acta Ophthalmol Scand. 2003;81:41-45.
18. Nicolson A, Leach JP, Chadwick DW, Smith DF. The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry. 2002;73:327-329.
19. Schmitz B. Visual field defects and vigabatrin: an update. Aktuelle Neurol. 2002;29:S24-S27.
20. Harding GFA, Wild JM, Robertson KA, Rietbrock S, Martinez C. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology. 2000;55:347-352.
21. Newman WD, Tocher K, Acheson JF. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye. 2002;16:567-571.
22. Frisen L, Malmgren K. Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand. 2003;81:466-473.
23. Bunsic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ. Characteristic retinal atrophy with secondary 'inverse' optic atrophy identifies vigabatrin toxicity in children. Ophthalmology. 2004;111:1935-1942.
24. Ravindran J, Blumbergs P, Crompton J, Pietris G, Waddy H. Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry. 2001;70:787-789.
25. Choi HJ, Kim DM. Visual field constriction associated with vigabatrin: retinal nerve fibre photographic correlation. J Neurol Neurosurg Psychiatry. 2004;75:1395.
26. Viestenz A, Viestenz A, Mardin CY. Vigabatrin-associated bilateral optic nerve atrophy with visual field construction: a case report and a survey of the literature. Ophthalmologue. 2003;100:402-405.
27. Paunescu LA, Schuman JS, Price LL, et al. Reproducibility of nerve fibre layer thickness, macular thickness and optic nerve head measurements using StratusOCT. Invest Ophthalmol Vis Sci. 2004;45:1716-1724.
28. Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia. 2001;42:262-267.
29. Harding GFA, Robertson KA, Edson AS, Barnes P, Wild JM. Visual electrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol. 1999;97:179-188.
30. Comaish IF, Gorman C, Brimlow GM, Barber C, Orr GM, Galloway N. The effects of vigabatrin on electrophysiology and visual field defects in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol. 2002;104:195-212.
31. Besch DA, Kurtenbach E, Apfelstedt-Sylla B, et al. Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol. 2002;104:151-170.
32. McDonagh J, Stephen LJ, Dolan FM, et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology. 2003;61:1690-1694.
33. Nousiainen I, Kalviainen R, Mantyjarvi M. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers. Br J Ophthalmol. 2000;84:622-625.
34. Roff Hilton EJ, Cubbidge RP, Hosking SL, Betts TA, Comish IF. Patients treated with vigabatrin exhibit central visual function loss. Epilepsia. 2002;43:1351-1359.
35. Nousiainen I, Kalviainen R, Mantyjarvi M. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. Ophthalmology. 2000;107:884-888.
36. Ozkul Y, Gurier B, Uckardes A, Bozlar S. Visual functions in epilepsy patients on valproate monotherapy. J Clin Neurosci. 2002;9:247-250.
37. Arndt CF, Salle M, Derambure PH, Defoort-Dhellemmes S, Hache JC. The effect on vision of associated treatments in patients taking vigabatrin: carbamazepine versus valproate. Epilepsia. 2002;43:812-817.
38. Sommer A, Katz J, Quigley HA, et al. Clinically detectable nerve fibre atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol. 1991;109:77-83.
39. Garway-Heath DF, Poinoosaumy D, Fitzke FW, Hitchings RA. Mapping the visual field to the optic disc in normal tension glaucoma eyes. Ophthalmology. 2000;107:1809-1815.
40. Schuman JS, Pedut-Kloizman T, Hertzmark E, et al. Reproducibility of nerve fibre layer thickness measurements using optical coherence tomography. Ophthalmology. 1996;103:1889-1898.
41. Carpiento P, Ciancaglini M, Zuppardi E, Falconio G, Doronzo E, Mastropasqua L. Reliability of nerve fibre layer thickness measurements using optical coherence tomography in normal and glaucomatous eyes. Ophthalmology. 2003;110:190-195.
42. Cense B, Chen TC, Park BH, Pierce MC, de Boer JF. Thickness and birefringence of healthy retinal nerve fibre layer tissue measured with polarization-sensitive optical coherence tomography. Invest Ophthalmol Vis Sci. 2004;45:2606-2612.